POPULATION PHARMACOKINETICS OF A NOVEL TGF-BETA RECEPTOR I KINASE INHIBITOR VACTOSERTIB IN PATIENTS WITH ADVANCED-STAGE SOLID TUMORS.

被引：0
|
作者：
Lee, J. I. [1 ]
Jung, S. Y. [1 ]
Yug, J. S. [2 ]
Chung, E. K. [2 ]
Keedy, V. L. [3 ]
Bauer, T. M. [4 ,5 ]
Clarke, J. M. [6 ]
Hurwitz, H. [6 ]
Lee, H. [7 ]
Park, N. [7 ]
Lee, S. [7 ]
Kim, H. -K. [7 ]
Baek, I. [8 ]
Hwang, S. [8 ]
Nam, S. Y. [8 ]
Ha, I. [8 ]
Kim, S. -J. [8 ]
机构：
[1] Seoul Natl Univ, Seoul, South Korea
[2] Kyung Hee Univ, Seoul, South Korea
[3] Vanderbilt Univ, Med Ctr, Nashville, TN USA
[4] Sarah Cannon Res Inst, Nashville, TN USA
[5] Tennessee Oncol, Nashville, TN USA
[6] Duke Univ, Med Ctr, Durham, NC USA
[7] Natl Canc Ctr, Natl OncoVenture, Goyang, South Korea
[8] MedPacto Inc, Suwon, South Korea
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2019年 / 105卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PIII-074
引用
收藏
页码：S103 / S103
页数：1
相关论文
共 50 条
  • [31] A phase I dose-escalation study of INCB028060, an inhibitor of c-MET receptor tyrosine kinase, in patients with advanced solid tumors.
    Donehower, R. C.
    Scardina, A.
    Hill, M.
    Bowman, J.
    Newton, R. C.
    Liu, X.
    Scherle, P.
    Wang, Q.
    Diamond, S.
    Boer, J.
    Lee, F.
    Gau, T.
    Burris, H. A.
    Bendell, J. C.
    Jones, S. F.
    Infante, J. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [32] Safety and pharmacokinetics of intravenous VEGF Trap in a phase I clinical trial of patients with advanced solid tumors.
    Dupont, J
    Rothenberg, ML
    Spriggs, DR
    Cedarbaum, JM
    Furfine, ES
    Cohen, DP
    Dancy, I
    Lee, HS
    Cooper, W
    Lockhart, AC
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 199S - 199S
  • [33] A phase I study of safety and pharmacokinetics of NanoBB-1-Dox in patients with advanced solid tumors.
    Filon, Olga
    Krivorotko, Petr
    Kobyakov, Grigory
    Razjivina, Viktoria
    Maximenko, Olga
    Gelperina, Svetlana
    Kreuter, Joerg
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [34] Phase I trial to assess the safety and pharmacokinetics of afatinib and weekly vinorelbine in patients with advanced solid tumors.
    Hollebecque, Antoine
    Bahleda, Rastislav
    Berge, Yann
    Massard, Christophe
    Uttenreuther-Fischer, Martina Maria
    De-Montserrat, Helene
    Tschoepe, Inga
    Soria, Jean-Charles
    Delord, Jean-Pierre
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [35] Phase I study of TT-00420, a multiple kinase inhibitor, as a single agent in advanced solid tumors.
    Piha-Paul, Sarina Anne Anne
    Xu, Binghe
    Janku, Filip
    Dumbrava, Ecaterina Elena
    Fu, Siqing
    Karp, Daniel D.
    Meric-Bernstam, Funda
    Hong, David S.
    Ahnert, Jordi Rodon
    Tsimberidou, Apostolia Maria
    Javle, Milind M.
    Fan, Ying
    Peng, Peng
    Levin, Wendy J.
    Ngo, Brenda
    Wang, Hui
    Sun, Caixia
    Ru, Qinhua Cindy
    Wu, Frank
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [36] Dose escalation stage of a first-in-class phase I study of the novel oral ERK 1/2 kinase inhibitor BVD-523 (ulixertinib) in patients with advanced solid tumors.
    Infante, Jeffrey R.
    Janku, Filip
    Tolcher, Anthony W.
    Patel, Manish R.
    Sullivan, Ryan J.
    Flaherty, Keith
    Carvajal, Richard D.
    Varghese, Anna M.
    Wong, Deborah Jean Lee
    Sznol, Mario
    Sosman, Jeffrey Alan
    Wang-Gillam, Andrea
    Burris, Howard A.
    Ribas, Antoni
    Patel, Sapna Pradyuman
    Welsch, Dean J.
    Saha, Saurabh
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [37] MGCD265, a multitargeted oral tyrosine kinase receptor inhibitor of Met and VEGFR, in combination with erlotinib in patients with advanced solid tumors.
    O'Dwyer, Peter J.
    Papadopoulos, Kyriakos P.
    Tolcher, Anthony W.
    Teitelbaum, Ursina R.
    Harlacker, Kathleen
    Smith, Lon S.
    Sohal, Davendra
    Rasco, Drew Warren
    Beeram, Muralidhar
    Mehran, Mariam
    Tawashi, Manal
    Drouin, Michel A.
    Wang, James
    Fournel, Marielle
    Maroun, Christiane R.
    Karam, Andre
    Besterman, Jeffrey M.
    Patnaik, Amita
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [38] Population Pharmacokinetics of Anlotinib, a Multiple Receptor Tyrosine Kinase Inhibitor, in Chinese Patients With Malignant Tumors
    Xu, Gaoqi
    Yang, Dihong
    Shu, Qi
    Zhu, Junfeng
    Ding, Haiying
    Xin, Wenxiu
    Zhong, Like
    Zhu, Liqin
    Fang, Luo
    JOURNAL OF CLINICAL PHARMACOLOGY, 2023, 63 (07): : 830 - 837
  • [39] Phase I trial of BAY 73-4506, a kinase inhibitor that targets oncogenic and angiogenic kinases, in patients with advanced solid tumors.
    Frost, A.
    Hedbom, S.
    Steinbild, S.
    Buchert, M.
    Unger, C.
    Christensen, O.
    Voliotis, D.
    Heinig, R.
    Mross, K.
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3459S - 3460S
  • [40] Phase I evaluation of telatinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in combination with bevacizumab in subjects with advanced solid tumors.
    Langenberg, M. H.
    Witteveen, P.
    Roodhart, J. M.
    Lolkema, M. P.
    Verheul, H.
    Mergui-Roelvink, M.
    Brendel, E.
    Kratzschmar, J.
    Schellens, J. H.
    Voest, E. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345